KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $987.2 million.

  • Royalty Pharma's Cash & Current Investments fell 4.36% to $955.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 11.56%. This contributed to the annual value of $987.2 million for FY2024, which is 99.31% up from last year.
  • According to the latest figures from FY2024, Royalty Pharma's Cash & Current Investments is $987.2 million, which was up 99.31% from $495.3 million recorded in FY2023.
  • Over the past 5 years, Royalty Pharma's Cash & Current Investments peaked at $1.7 billion during FY2022, and registered a low of $495.3 million during FY2023.
  • For the 3-year period, Royalty Pharma's Cash & Current Investments averaged around $1.1 billion, with its median value being $987.2 million (2024).
  • Per our database at Business Quant, Royalty Pharma's Cash & Current Investments skyrocketed by 2,976.44% in 2020 and then tumbled by 71.07% in 2023.
  • Royalty Pharma's Cash & Current Investments (Yearly) stood at $1.1 billion in 2020, then skyrocketed by 48.99% to $1.6 billion in 2021, then increased by 6.53% to $1.7 billion in 2022, then slumped by 71.07% to $495.3 million in 2023, then soared by 99.31% to $987.2 million in 2024.